Original Article

Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia

K.A. Graham, R.S. Keefe, J.A. Lieberman, A.S. Calikoglu, K.M. Lansing and D.O. Perkins

Abstract

Aim: Deficient vitamin D levels are very common among Americans of all ages and ethnicities, but little is known about its prevalence or associated problems among those with schizophrenia.

Methods: Stored plasma from 20 recent onset schizophrenia subjects and 20 matched healthy comparison subjects were analysed for 25 OH vitamin D, and related to measures of symptom severity and neurocognition.

Results: There was no significant difference in mean 25 OH vitamin D between the schizophrenia and the healthy comparison subjects (28.2 standard deviation (SD) 12.6 ng mL\(^{-1}\) vs. 29.9 SD 14.3 ng mL\(^{-1}\)), and about half the subjects in each group had insufficient levels (<30 ng mL\(^{-1}\)). Among psychosis subjects, greater severity of negative symptoms was correlated with lower vitamin D status (\(r = -0.55, P = 0.012\)); the correlations of overall symptom severity and positive symptom severity with 25 OH vitamin D levels approached significance (\(r = -0.42, P = 0.07\) and \(r = -0.36, P = 0.12\), respectively). There was no relationship of vitamin D with depressive symptoms. Among the schizophrenia subjects, lower 25 OH vitamin D levels were associated with more severe overall cognitive deficits (\(r = 0.56, P = 0.019\)).

Conclusion: This study found that lower vitamin D levels in schizophrenia subjects were associated with more severe negative symptoms and overall cognitive deficits. However, the cross-sectional design precludes any conclusions about whether low vitamin D status in fact causes more severe negative symptoms and cognitive impairments. No relationship was found between lower vitamin D levels and depressive symptoms.

Key words: complementary and alternative treatment, neurocognition, schizophrenia, symptoms, vitamin D.

INTRODUCTION

There is growing recognition of the importance of adequate vitamin D levels to overall health, including brain health. At the same time, there is recognition of a worldwide epidemic of vitamin D insufficiency.\(^{1,2}\) Although the importance of sunlight and vitamin D to bone health has been known for hundreds of years, it is only recently that they are being linked to other disease states, such as multiple sclerosis,\(^{3}\) prostate,\(^{4}\) breast and colorectal\(^{5}\) cancers, Parkinson’s disease,\(^{6}\) diabetes mellitus\(^{7}\) and the metabolic syndrome.\(^{8}\) Adequate vitamin D status is also needed for optimal muscular strength in youth (HELENA study) and the elderly.\(^{9}\) In addition to these diseases, vitamin D has also been linked to mental illnesses including Alzheimer’s,\(^{10}\) premenstrual mood disorder,\(^{11,12}\) major depression\(^{13}\) and psychosis.\(^{14}\) However, the relationship of vitamin D status to the functions of the brain is also in its infancy,\(^{14}\) with some evidence of negative, cognitive\(^{15-17}\) and mood\(^{18,19}\) effects in people with insufficient vitamin
Vitamin D and schizophrenia symptoms

D levels. Neuroprotective qualities of vitamin D have been observed in animal studies, and recent reviews have suggested that vitamin D could play an important role in the central nervous system for healthy neural development and function. A correlation between schizophrenia and low prenatal and early life vitamin D status has been well demonstrated, and supplementation could be important for disease prevention. However, the influence of low vitamin D status on symptom severity in adults with schizophrenia, although hypothesized, has only begun to be investigated. It has been found that patients with schizophrenia have lower vitamin D levels compared with healthy subjects or those with depression. It has also been established that adolescent patients with lower vitamin D levels were 3.5 times more likely to have psychotic features than their unaffected counterparts and those that did not have psychotic features. In a sample of active duty military members, subjects with the highest suicide risk had the lowest vitamin D levels. A recent meta-analysis also found that lower vitamin D levels are associated with greater risk for developing Alzheimer’s and poorer cognitive performance. Although recent studies have emerged showing that lower vitamin D levels are associated with symptoms common to schizophrenia, more research is needed to determine if vitamin D insufficiency contributes to symptom severity in schizophrenia. To this end, we assessed the relationship of vitamin D status with measures of positive, negative, cognitive and depressive symptoms in otherwise healthy young adults with schizophrenia.

METHODS

Subject characteristics

Outpatient subjects participating in two longitudinal first-episode schizophrenia research projects at the University of North Carolina at Chapel Hill consented to have blood drawn and stored in a biospecimen bank as approved by the University of North Carolina at Chapel Hill Investigational Review Board. Diagnosis in the schizophrenia subjects was made using the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (SCID) administered by an experienced masters-level clinician (n = 17 schizophrenia, n = 2 schizoaffective and n = 1 schizoaffective). For the remainder of this paper, all subjects with a psychotic disorder will be referred to as schizophrenia subjects. Duration of psychosis was less than 5 years, and subjects had not received more than 16 weeks of cumulative antipsychotic treatment. Schizophrenia patients did not have clinically significant neurological or medical disorders that could influence the diagnosis, and did not have a history of or current diagnosis of substance dependence or current substance abuse. For each schizophrenia subject, a healthy control subject was matched for age, ethnicity and gender. For schizophrenia subjects, ages ranged from 19 to 26 for men and from 17 to 33 for women; for controls ages ranged from 19 to 26 for men and from 20 to 33 for women. Additionally, the month of blood draw was the same for the schizophrenia/healthy pair to control for the effects of sun exposure on vitamin D level. Healthy subjects did not have relevant current or past psychiatric or physical illness as determined by psychiatric and physical examination and laboratory testing including toxicology screening.

Procedures and evaluations

At the time that the blood specimen was obtained each subject underwent neurocognitive testing. There were some differences among the tests used in the two studies; however the five key domains of verbal fluency, attention, processing speed, visual working memory and executive functioning were evaluated with the same neurocognitive test in both studies (Table 1). These test procedures were identical for all study subjects, and supervision of test administration was conducted by the same study investigator (RSK). To create a summary cognitive score, the results of each test were standardized to the mean and standard deviation of the subject’s group, and the standard scores averaged together.

All schizophrenia subjects had clinical evaluations that included the Positive and Negative Syndrome Scale (PANSS) and the Calgary Depression Rating Scale (CDRS), conducted by trained, experienced masters-level clinicians. The PANSS positive subscale was the sum of items delusions, conceptual disorganization, hallucinations, hyperactivity, grandiosity, suspiciousness and hostility. The PANSS negative subscale was the sum of items blunted affect, emotional withdrawal, poor rapport, passive-apathetic social withdrawal, abstract thinking, lack of spontaneity and stereotyped thinking.

Vitamin D assay methods

All samples used in this analysis were drawn between November 2002 and November 2004, except one outlier comparison sample drawn in February 2006. All samples were biobanked at baseline, prior to any study procedures. Serum samples from
schizophrenia and control subjects were stored at −80°C. In November 2010, serum from 20 schizophrenia subjects and 20 matched controls were analysed for vitamin D status. Although we did not perform internal validation studies to verify the stability of the vitamin D samples, the literature clearly indicates that 25-hydroxy vitamin D (25OHD) is stable at least 40 years if samples are stored at −20°C or lower.39 Serum vitamin D was measured by chemiluminescent immunoassay as 25OHD using the ISYS Autoanalyzer (Immunodiagnostic Systems, Inc., Scottsdale, AZ, USA) at the Clinical and Translational Research Lab of the Maine Medical Center Research Institute, Scarborough, Maine. Vitamin D levels were classified as insufficient if the value of 25OHD was <30 ng mL\(^{-1}\) and sufficient if the value was ≥30 ng mL\(^{-1}\).40,41

Statistical methods
Baseline characteristics were compared using Student \(t\)-tests for continuous variables and chi-squared test for dichotomous variables. We compared mean 25OHD levels between schizophrenia and comparison subjects using a Student’s \(t\)-test. We determined the relationship of 25OHD with neurocognitive function and symptom severity measures using general linear modelling, reporting unadjusted and age, sex and years of education adjusted results. Statistical analyses were conducted using SAS (Cary, NC, USA).

RESULTS

Comparison of first-episode schizophrenia and healthy control groups for demographic variables and 25OHD

There were no significant differences between the schizophrenia and the control groups for age, sex or ancestry (see Table 2). The mean 25OHD level of the two groups was also similar (28.2 ± 12.6 ng mL\(^{-1}\) for the schizophrenia group and 29.9 ± 14.3 ng mL\(^{-1}\) for the control group). Caucasian subjects had

| Domain                  | Test                                                      | Description                                                                 |
|-------------------------|-----------------------------------------------------------|-----------------------------------------------------------------------------|
| Verbal fluency          | Controlled Oral Word Association Test (COWAT)             | Subjects are asked to generate as many words as possible beginning with F, A and S in three separate trials of 60 s. |
|                         | Category Instance Generation (CIG)                        | Subjects are asked to name as many words as possible in 60 s within each of three categories (animals, fruits, vegetables). |
| Attention               | Continuous Performance Test (CPT)                         | Subjects are asked to respond to a series of 450 two-digit numbers and then a second series of 450 four-digit numbers presented on a computer screen at a rate of one per second by lifting a finger from a mouse key whenever the number is identical to the previous number in the series. |
| Processing speed        | WAIS-R Digit Symbol Test (Digit Symbol)                   | Each number (one through nine) is associated with a different simple symbol, and the subject is asked to copy as many symbols associated with the numbers as possible in 90 s. |
| Visual working memory   | Computerized Task of Visuo-Spatial Working Memory (CTVSWM)| Subject focus on a cross on a computer screen. While the cross is fixated, a cue appears for 150 ms in one of 32 possible locations at a 4.5-inch radius from the cross. A delay period (5 or 15 s) is then imposed. During the delay, a series of geometric shapes appears in place of the fixation cross. The subject must press the space bar whenever the diamond shape appears. After the delay, the cross returns, and the subject must point on the computer screen where they remember seeing the cue. Mean error in millimetres (distance between recall and actual target) is calculated for each subject for each type of trial. |
| Executive function      | Wisconsin Card Sorting Task (WCST)                        | Subjects sort a series of stimulus cards that differ by shape, colour and number, with the correct sorting strategy changing after 10 consecutive correct responses. The number of perseverative errors, completed number of categories and additional consecutive cards in the final category is scored. |

© 2014 The Authors Early Intervention in Psychiatry Published by Wiley Publishing Asia Pty Ltd
significantly higher 25OHD levels compared with African American subjects (32.07 ± 12.6 vs. 14.55 ± 5.7 ng mL−1; \( P < 0.0001 \)), and women had significantly higher levels compared with men (37.0 ± 13.3 vs. 23.8 ± 10.6 ng mL−1; \( P < 0.001 \)). When considering only Caucasian subjects the 25OHD levels were still significantly (\( P = 0.03 \)) lower for men (27.5 ± 10.2 ng mL−1) than women (37.0 ± 13.3 ng mL−1). The level of 25OHD did not vary with age (range 17–30 years) or years of education.

Vitamin D status and symptom severity in first-episode schizophrenia subjects

Within the schizophrenia subjects, there was no relationship of age, sex or years of education with any measure of symptom severity, with the exception of sex and positive symptoms (\( \chi^2 = 5.4, P = 0.02 \)). Within the schizophrenia group, more severe negative symptoms were associated with low vitamin D level (adjusted \( \chi^2 = 4.78, P = 0.03 \); age-, sex- and education-adjusted \( \chi^2 = 7.36, P = 0.007 \)) (Fig. 1a) and total symptom severity (unadjusted \( \chi^2 = 4.52, P = 0.03 \); age-, sex- and education-adjusted \( \chi^2 = 5.90, P = 0.02 \)) (Fig. 1b); positive symptom severity were associated with lower 25OHD at a trend level (unadjusted \( \chi^2 = 3.73, P = 0.053 \); age-, sex- and education-adjusted \( \chi^2 = 2.05, P = 0.15 \)) (Fig. 1c). There was no relationship of 25OHD with depressive symptoms as measured by the CDRS. Schizophrenia subjects with insufficient vitamin D on average had significantly lower scores on the total PANSS and the negative symptom subscale, with a trend towards lower positive symptom subscale scores (see Table 3).

Vitamin D status and neurocognitive results in first-episode schizophrenia subjects and healthy control subjects

Among the schizophrenia subjects, lower 25OHD levels were associated with more severe cognitive deficits as measured by the cognition summary score (unadjusted \( \chi^2 = 9.03, P = 0.003 \); age-adjusted \( \chi^2 = 8.96, P = 0.003 \); sex-adjusted \( \chi^2 = 4.05, P = 0.04 \); education-adjusted \( \chi^2 = 5.53, P = 0.02 \); full model-adjusted \( \chi^2 = 2.0, P = 0.16 \)) (Fig. 2a). Within the individual test results, only lower verbal fluency scores were associated with low vitamin D status in this group, but this relationship did not remain after adjustment for sex (unadjusted \( \chi^2 = 7.2, P = 0.007 \)).

We did not find a relationship between 25OHD levels and cognitive function in healthy control subjects (Fig. 2b). Additionally, there was not a significant difference in performance on the neurocognitive summary score or individual domains for healthy control subjects with insufficient compared with sufficient vitamin D status.

DISCUSSION

This study is the first, to our knowledge, to report an association of vitamin D insufficiency and more severe negative symptoms and poorer neurocognitive function in patients with schizophrenia. These findings lead us to hypothesize that inadequate vitamin D status may account for some portion of the symptom burden experienced by persons with schizophrenia. As much of the disability experienced by persons with schizophrenia is related to severity of negative and cognitive symptoms and there are currently no approved pharmacologic methods to treat these symptoms, we hypothesize that correcting vitamin D insufficiency in schizophrenia could fill a critical role. It has been shown that dietary intake of vitamin D is associated with decreased risk of moderate and high-level psychotic symptoms in women from the general population in Sweden. It is conceivable that vitamin D replacement could be a low-cost intervention that may reduce symptom burden in patients with schizophrenia who have low 25OHD levels. Even in the absence of definitive studies showing benefit of vitamin D supplementation for cognition and negative symptoms, correction of insufficient vitamin D status is strongly recommended for

Vitamin D and schizophrenia symptoms

| TABLE 2. Demographics and 25OHD levels for first-episode schizophrenia subjects and healthy control subjects |
|---------------------------------------------------|---------------------------------------------------|----------------|
| **Schizophrenia subjects** (\( n = 20 \)) | **Healthy control subjects** (\( n = 20 \)) | \( P \)-value |
| Mean age (SD) | 23 (3.8) | 24.5 (3.9) | NS |
| % male (n) | 60 (12) | 60 (12) | NS |
| % Caucasian (n) | 85 (17) | 85 (17) | NS |
| Mean 25OHD (ng mL−1) | 28.2 (12.6) | 29.9 (14.3) | NS |

NS, not significant; SD, standard deviation; 25OHD, 25-hydroxy vitamin D.
prevention of osteoporosis, and there is growing evidence for prevention of cancers, cardiovascular illness and diabetes.

There is convincing evidence that vitamin D has a role in healthy brain function. The vitamin D receptor and the enzyme needed for the hydroxylation of the precursor molecule 25OHD to the active form, 1-α-hydroxylase, have widespread expression in the adult human brain. Many of these brain regions are implicated in schizophrenia, including the hippocampus, thalamus, hypothalamus, amygdala, prefrontal cortex, cingulate gyrus and temporal lobe. Evidence of a correlation between development of schizophrenia and low prenatal and early life vitamin D status has been demonstrated in many studies. There is a highly significant peak in schizophrenia births in winter time, when risk of vitamin D deficiency is high. Incidence of schizophrenia is higher in immigrants, especially dark-skinned people moving to higher latitudes, a scenario which promotes low vitamin D levels. A Finnish birth cohort study showed that vitamin D supplementation of at least 2000 IU per day in male infants during the first year of life reduced the risk of developing schizophrenia by 77% compared with those receiving less than 2000 IU per day. Finally, low maternal vitamin D status may increase the subsequent risk of schizophrenia in the developing fetus. A plausible role in schizophrenia pathology is also suggested by the finding that vitamin D acts to regulate transcription of many genes involved in pathways implicated in schizophrenia, including genes involved in synaptic plasticity, neuronal development and protection against oxidative stress.

In this study, those with schizophrenia were no more likely to have insufficient vitamin D than those in the healthy control group, indicating that low vitamin D status in late adolescence or early adulthood is unlikely to be causally related to schizophrenia risk in these subjects. We matched control subjects to patients based on sex, age and date of blood draw, three important factors affecting vitamin D level. Unfortunately, we were unable to control for body mass index (BMI), smoking status, dietary vitamin D intake and activity level that are other important factors affecting vitamin D status. Additionally, there was little ethnic diversity in the sample that will limit the ability to generalize results to different populations. A particular strength of this study is that all subjects did not receive more than 16 weeks of cumulative antipsychotic treatment, and duration of psychosis was less than 5 years. Despite this, exposures of this length of time may be sufficient to impact vitamin D status through increases in BMI. It is hypothesized that antipsychotic associated hyperprolactinaemia is a risk factor for osteoporosis by causing hypogonadism, but it is not known whether there are direct effects of the antipsychotic medications on vitamin D status. Despite all of these risk factors for low vitamin D status, an equal percentage of the first-episode schizophrenia and healthy control subjects had insufficient 25OHD levels, roughly half. Two other
small studies from Europe similarly found low vitamin D levels in about half of adult schizophrenia patients. A recent study of 136 adolescents consecutively admitted to inpatient psychiatry units in France found an alarming 95.5% had 25OHD below the recommended 30 ng mL\(^{-1}\), but with no correlation between use of antipsychotics, gender or BMI and vitamin D status. Future studies to elucidate the impact of antipsychotic medications on vitamin D status are needed.

The relationship of vitamin D status to cognitive function has only been investigated in observational studies to date. Most recently, a large database analysis of 3325 American adults aged 65 years and older from the Third National Health and Nutrition Examination Survey (NHANES III) found that vitamin D deficiency was associated with increased odds of cognitive impairment. These results are in keeping with another population study of 752 women aged 75 years and older living in France. Those with vitamin D deficiency (<10 ng mL\(^{-1}\)) had lower scores on the Pfeiffer Short Portable Mental State Questionnaire compared with those with greater vitamin D levels \((P<0.001)\). The same investigators looked at a larger sample of 5596 community-dwelling women in France (mean age 80 years) and found that those with inadequate dietary intake of vitamin D (<35 µg week\(^{-1}\)) had significantly lower mean cognitive scores on the Pfeiffer Short Portable Mental State Questionnaire compared with those with greater vitamin D levels. However, Slinin and colleagues\(^{53}\) did not find significant difference in cognitive functioning using the modified mini-mental state examination (MMSE), and lack of correlation between 25OHD and measures of executive and learning functions have also been reported.\(^{54,55}\) Similarly, low vitamin D levels were found to be common among geriatric inpatients, but there was no relationship between MMSE scores and vitamin
that 25OHD levels below 12 ng mL\(^{-1}\) be considered indicative of deficiency and between 12 and 20 ng mL\(^{-1}\) indicative of insufficiency.\(^\text{58}\) However, these recommendations are very controversial as levels in this range have been implicated in numerous human disorders including cardiovascular disease, diabetes, cancer, multiple sclerosis, allergy, asthma and obesity.\(^\text{33,35}\) For these reasons, a 25OHD level at or above 30 ng mL\(^{-1}\) is recommended by many clinicians and researchers\(^\text{59}\) as optimal for good health and disease prevention, and with some finding additional benefits up to 60 ng mL\(^{-1}\).\(^\text{60}\) Our preliminary findings are consistent with the vast majority of published work that supports a need for higher vitamin D intake for most persons living in temperate climates. Oral supplementation with vitamin D\(_3\) is inexpensive and toxicity occurs only with very high doses.\(^\text{50,61}\)

Our study involves only 20 subjects early in the course of schizophrenia and 20 matched healthy comparison subjects. With this small sample size, there may be both Type I errors, as we did not correct for multiple comparisons, and Type II errors, that is, missing more subtle adverse effects of insufficient vitamin D status on schizophrenia symptoms. In addition, the question of reverse causality (worse negative and cognitive symptoms leading to lower vitamin D status) can never be conclusively answered in a cross-sectional study such as this one. Although the results of our pilot study raise important questions for patients with schizophrenia, it is premature to draw any conclusions regarding whether vitamin D supplementation can improve schizophrenia symptoms. Treatment recommendations for schizophrenia cannot be made based on these findings, but require well-designed placebo controlled clinical trials.

ACKNOWLEDGEMENTS

The authors wish to thank Dr Hongbin Gu for her assistance with the analysis.

REFERENCES

1. Ginde AA, Liu MC, Camargo CA Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988–2004. Arch Intern Med 2009; 169: 626–32.
2. McKenna MJ. Differences in vitamin D status between countries in young adults and the elderly. Am J Med 1992; 93: 69–77.
3. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 296: 2832–8.
4. Polek TC, Weigel NL. Vitamin D and prostate cancer. J Androl 2002; 23: 9–17.
Vitamin D and schizophrenia symptoms

5. Grant WB. Relation between prediagnostic serum 25-hydroxyvitamin D level and incidence of breast, colorectal, and other cancers. J Photochem Photobiol B 2010; 101: 130–6.

6. Evatt M, DeLong M, Khazai N, Rosen A, Triche A, Tangpricha V. Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol 2008; 65: 1348–52.

7. Scragg R, Sowers M, Bell D. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 2004; 27: 2813–18.

8. Lind L, Hanni A, Lithell H, Hvarfner A, Sorenson OH, Ljunghall S. Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am J Hypertens 1995; 8: 894–901.

9. Hirani V, Naganathan V, Cumming RG et al. Associations between frailty and serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations in older Australian men: the concord health and ageing in men project. J Gerontol A Biol Sci Med Sci 2013; 68: 1112–21.

10. Balion C, Griffith L, Strifler L et al. Vitamin D and aggression: a systematic review and meta-analysis. Neurology 2012; 79: 1397–405.

11. Eskandari F, Martinez P, Torvik S. Vitamin D and aggression in older postmenopausal women with depression. Arch Intern Med 2007; 167: 2239–36.

12. Thys-Jacobs S, Silberton M, Alvir J, Paddison P, Rico M, Coldsmith R. Reduced bone mass in women with premenstrual syndrome. J Womens Health 1995; 4: 161–8.

13. Gracious B, Finucane T, Friedman-Campbell M, Messing S, Parkhurst M. Vitamin D deficiency and psychotic features in mentally ill adolescents: a cross-sectional study. BMC Psychiatry 2012; 12: 38.

14. Garcia E, Wion D. New clues about Vitamin D functions in the nervous system. Trends Endocrinol Metab 2002; 13: 100–5.

15. Annweiler C, Schott AM, Allali G et al. Association of vitamin D deficiency with cognitive impairment in older women: cross-sectional study. Neurology 2010; 74: 27–32.

16. Annweiler C, Schott AM, Rolland Y, Blain H, Herrmann FR, Beachet O. Dietary intake of vitamin D and cognition in older women: a large population-based study. Neurology 2010; 75: 1810–16.

17. Llewellyn DJ, Lang IA, Langa KM, Melzer D. Vitamin D and cognitive impairment in the elderly U.S. population. J Gerontol A Biol Sci Med Sci 2010; 66: 59–65.

18. Jorde R, Sneve M, Figenschau Y, Svartberg J, Waterloo K. Vitamin D deficiency and increased suicide risk: results from the Copenhagen General Population Study. J Psychiatr Res 2010; 44: 1065–70.

19. Parkhurst M. Vitamin D deficiency and psychotic features in women with schizophrenia. J Nutr Health Aging 2012; 161–71.

20. Umhau J, George D, Heaney R et al. Low vitamin D status and suicide: a case-control study of active duty military service members. PLoS ONE 2013; 8: e51543.

21. Valtueña J, Gracia-Marco L, Huybrechts I et al. Factors associated with vitamin D deficiency in European adolescents: the Helena Study. J Nutr Sci Vitaminol (Tokyo) 2013; 59: 161–71.

22. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I-P). New York: Biometrics Research, New York State Psychiatric Institute, 2002.

23. Benton AL, Hamsher K. Controlled Oral Word Association Test. Multilingual Aphasia Examination Manual (revised). 1978.

24. Benton AL, Hamsher K. Category Instance. Multilingual Aphasia Examination Manual (revised). 1978.

25. Wechsler D. Wechsler Adult Intelligence Scale-Revised, Digit Symbol Test. Wechsler Adult Intelligence Scale, Revised Edition. 1974.

26. Kongs SK, Thompson LL, Iverson GL, Heaton RK. Wisconsin Card Sorting Test, 64-card computerized version. Professional Manual. Psychological Assessment Resources, Inc. 2000.

27. Lyons-Warren A, Lillie R, Hershey T. Computerized Test of Visuospatial Working Memory. 2004.

28. Lyons-Warren A, Lillie R, Hershey T. Short and long-term spatial delayed response performance across the lifespan. Dev Neuropsychol 2004; 26: 661–78.

29. Cornblatt BA, Keilp JG. Continuous Performance Test (CPT). Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr Bull 1994; 20: 31–46.

30. Kay SR, Fiszbein A, Opier LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–76.

31. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl 1993; 22: 39–44.

32. Agborsangaya C, Toniola A, Granovskit K. The effects of storage times and sampling on the stability of serum 25-hydroxyvitamin D and 25-hydroxyvitamin D in blood and plasma samples. Int J Vitam Nutr Res 2010; 80: 214–19.

33. Wion D. New clues about Vitamin D functions in the nervous system. Trends Endocrinol Metab 2002; 13: 100–5.

34. Lyons-Warren A, Lillie R, Hershey T. Short and long-term spatial delayed response performance across the lifespan. Dev Neuropsychol 2004; 26: 661–78.

35. Cornblatt BA, Keilp JG. Continuous Performance Test (CPT). Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr Bull 1994; 20: 31–46.

36. Kay SR, Fiszbein A, Opier LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–76.

37. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl 1993; 22: 39–44.

38. Agborsangaya C, Toniola A, Grantwist K. The effects of storage times and sampling on the stability of serum 25-hydroxyvitamin D and 25-hydroxyvitamin D in blood and plasma samples. Int J Vitam Nutr Res 2010; 80: 214–19.

39. Holick MF. Vitamin D deficiency. Mayo Clin Proc 2011; 86: 50–60.

40. Mohamed S, Rosenheck R, Swartz S, Stroup S, Lieberman JA, Keefe RS. Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am J Psychiatry 2008; 165: 978–87.

41. Hedin M, Löf M, Olsson M et al. Dietary intake of fish, omega-3, omega-6 polyunsaturated fatty acids and vitamin D and the prevalence of psychotic-like symptoms in a cohort of 33 000 women from the general population. BMC Psychiatry 2010; 10: 38. doi: 10.1186/1471-244X-10-38.

42. van den Bergh JP, Bours SP, van Geel TA, Geusens PP. Optimal cut-off points for vitamin D deficiency: a systematic review. Arch Osteoporos Rep 2011; 9: 36–42.

43. Grant WB, Cross HS, Garland CF et al. Estimated benefit of increased vitamin D status in reducing the economic burden of disease in Western Europe. Prog Biophys Mol Biol 2009; 99: 104–13.
46. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat 2005; 29: 21–30.

47. Fernandes de Abreu A, Eyles D, Feron F. Vitamin D, a neuroimmunomodulator: implications for neurodegenerative and autoimmune diseases. Psychoneuroendocrinology 2009; 34: S265–77.

48. Meaney AM, Smith S, Howes OD, O’Brien M, Murray RM, O’Keane V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 2004; 184: 503–8.

49. Humble MB, Gustafsson S, Bejerot S. Low serum levels of 25-hydroxyvitamin D (25-OHD) among psychiatric outpatients in Sweden: relations with season, age, ethnic origin and psychiatric diagnosis. J Steroid Biochem Mol Biol 2010; 121: 467–70.

50. Schneider B, Weber B, Frensch A, Stein J, Fritz J. Vitamin D in schizophrenia, major depression and alcoholism. J Neural Transm 2000; 107: 839–42.

51. Bonnot O, Inaoui R, Raffin-Viard M, Bodeau N, Coussieu C, Cohen D. Children and adolescents with severe mental illness need vitamin D supplementation regardless of disease or treatment. J Child Adolesc Psychopharmacol 2011; 2: 157–61.

52. van der Schaft J, Koek H, Dijkstra E, Verhaar H, van der Schouw Y, Emmelot-Vonk M. The association between vitamin D and cognition: a systematic review. Ageing Res Rev 2013; 12: 1013–1023.

53. Slinin Y, Paudel ML, Taylor BC et al. 25-Hydroxyvitamin D levels and cognitive performance and decline in elderly men. Neurology 2010; 74: 33–41.

54. Wilkins CH, Birge SJ, Sheline YI, Morris JC. Vitamin D deficiency is associated with worse cognitive performance and lower bone density in older African Americans. J Natl Med Assoc 2009; 101: 349–54.

55. McGrath J, Scragg R, Chant D, Eyles D, Burne T, Obradovic D. No association between serum 25-hydroxyvitamin D3 level and performance on psychometric tests in NHANES III. Neuroepidemiology 2007; 29: 49–54.

56. Lapid M, Drake M, Geske J et al. Hypovitaminosis D in psychogeriatric inpatients. J Nutr Health Aging 2013; 17: 231–4.

57. Gloth F, Alam W, Hollis B. Vitamin D vs broad spectrum phototherapy in the treatment of seasonal affective disorder. J Nutr Health Aging 1999; 3: 5–7.

58. Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Press, 2010. [Cited 25 Apr 2013.] Available from URL: http://www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D.aspx

59. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int 2005; 16: 713–16.

60. Garland CF, French CB, Baggerly LL, Heaney RP. Vitamin D supplement doses and serum 25-hydroxyvitamin d in the range associated with cancer prevention. Anticancer Res 2011; 31: 607–11.

61. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentration, and safety. Am J Clin Nutr 1999; 69: 842–56.